VYNE VYNE Therapeutics Inc.
No recent data for VYNE. Our end-of-day feed has carried no price for this security since 2026-07-27, and we found no SEC delisting or deregistration filing that would explain it — so this reflects the coverage of our data source. The security may still be trading, and quotes may be available elsewhere. Company filings and reported financials on this page are unaffected.
Updated
Healthcare · Pharmaceutical Preparations
VYNE Therapeutics Inc. (VYNE) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $936 million. Price data for VYNE is unavailable — our feed has carried no quote since 2026-07-27. Revenue grew 13.8% year over year.
Chart hidden: no price data for VYNE since 2026-07-27. Company filings and financials below are current.
Financials
Latest reported annual period ending 2026-03-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $-0.08 | 2026-05-15 |
| FY 2025 | $-0.62 | 2026-02-27 |
| Q2 2025 | $-0.34 | 2025-08-14 |
| Q1 2026 | $-0.20 | 2026-05-15 |
| FY 2025 | $-0.93 | 2026-02-27 |
| Q3 2024 | $-0.65 | 2024-11-07 |
Pharmaceutical Preparations peers
VYNE vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
| REGN | Regeneron Pharmaceuticals | $87.2B | 20.15 | 5.61 | 27.9% | -1.02% |
| TEVA | Teva Pharmaceutical Industries Ltd | $42.6B | 60.41 | 2.46 | 4.1% | -2.32% |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 43.77 | 9.52 | 21.8% | -1.10% |
| ZTS | Zoetis | $31.5B | 12.05 | 3.31 | 27.5% | +0.16% |
| RPRX | Royalty Pharma Plc | $28.2B | 34.56 | 11.11 | 32.1% | +1.24% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.